Literature DB >> 26600115

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.

D R Matthews1, B Zinman2, C Tong3, G Meininger3, D Polidori4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26600115     DOI： 10.1111/dme.13033

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  3 in total

Review 1.  Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Authors:  Matthew J Budoff; John P H Wilding
Journal:  Int J Clin Pract       Date:  2017-05       Impact factor: 2.503

2.  Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

Authors:  Nobuya Inagaki; Shin-Ichi Harashima; Nobuko Maruyama; Yutaka Kawaguchi; Maki Goda; Hiroaki Iijima
Journal:  Cardiovasc Diabetol       Date:  2016-06-18       Impact factor: 9.951

3.  Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes.

Authors:  Edward Shahady; John L Leahy
Journal:  Clin Diabetes       Date:  2019-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.